IP Library Granted Patent US 7,763,718
Granted Patent B2
US 7,763,718 · App. 11/926,391 · Granted Jul 27, 2010

Soluble T cell receptors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,718
App. No.
11/926,391
Granted
Jul 27, 2010
Kind
B2
Abstract

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR α chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.

Claims (39)

1. An isolated nucleic acid molecule comprising a sequence encoding all or part of a TCR α chain, except the transmembrane domain thereof,

wherein the all or part of the TCR α chain comprises a functional variable domain and at least a part of the constant domain of the TCR α chain, and wherein the all or part of the TCR α chain comprises a cysteine residue substituted for an amino acid selected from the group consisting of:

(a) Thr 48 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:1);

(b) Thr 45 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:2);

(c) Tyr 10 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:3); and

(d) Ser 15 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:4).

2. The nucleic acid molecule of claim 1 which encodes all of the extracellular constant Ig domain of the TCR α chain.

3. A vector comprising a nucleic acid molecule comprising a sequence encoding all or part of a TCR α chain, except the transmembrane domain thereof, wherein the all or part of the TCR α chain comprises a functional variable domain and at least a part of the constant domain of the TCR α chain, and wherein the all or part of the TCR α chain comprises a cysteine residue substituted for an amino acid selected from the group consisting of

(a) Thr 48 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:1);

(b) Thr 45 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:2);

(c) Tyr 10 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:3); and

(d) Ser 15 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:4).

4. An isolated host cell comprising the vector of claim 3 .

5. A method for producing a soluble TCR, said method comprising:

(i) transforming a first host cell with a nucleic acid molecule encoding a TCR α chain comprising a non-native cysteine residue in a first position of the constant domain thereof;

(ii) transforming a second host cell with a nucleic acid molecule encoding a TCR β chain comprising a non-native cysteine residue in a second position of the constant domain thereof;

(iii) incubating said host cells under conditions causing expression of the TCR chains;

(iv) refolding the TCR chains in a refolding buffer; and

(v) isolating the refolded soluble TCR,

wherein the non-native cysteine residues are substituted for native residues whose β carbon atoms are 0.6 nm or less apart in the native TCR structure and wherein the refolded soluble TCR comprises a disulfide bond formed from cysteine residues substituted for amino acid residues selected from the group consisting of:

(a) Thr 48 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:1) and Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:5);

(b) Thr 45 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:2) and Ser 77 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:6);

(c) Tyr 10 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:3) and Ser 17 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:7);

(d) Thr 45 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:2) and Asp 59 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:8); and

(e) Ser 15 of exon 1 of TRAC*01 (amino acid residue 10 of SEQ ID NO:4) and Glu 15 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:9).

6. An isolated nucleic acid molecule comprising a sequence encoding all or part of a TCR β chain, except the transmembrane domain thereof, wherein the all or part of the TCR β chain comprises a functional variable domain and at least a part of the constant domain of the TCR β chain, and wherein the all or part of the TCR β chain comprises a cysteine residue substituted for an amino acid selected from the group consisting of:

(a) Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:5);

(b) Ser 77 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:6);

(c) Ser 17 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:7);

(d) Asp 59 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:8); and

(e) Glu 15 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:9).

7. The nucleic acid molecule of claim 6 which encodes all of the extracellular constant Ig domain of the TCR β chain.

8. A vector comprising comprising a sequence encoding all or part of a TCR β chain, except the transmembrane domain thereof, wherein the all or part of the TCR β chain comprises a functional variable domain and at least a part of the constant domain of the TCR β chain, and wherein the all or part of the TCR β chain comprises a cysteine residue substituted for an amino acid selected from the group consisting of:

(a) Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:5);

(b) Ser 77 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:6);

(c) Ser 17 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:7);

(d) Asp 59 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:8); and

(e) Glu 15 of exon 1 of TRBC1*01 or TRBC2*01 (amino acid residue 10 of SEQ ID NO:9).

9. An isolated host cell comprising the vector of claim 8 .

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Nov 11, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOCORE LIMITED
Reel/Frame 069197/0672 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2022
From: OXFORD FINANCE LUXEMBOURG S.À R.L
To: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
Reel/Frame 061916/0493 →
PATENT SECURITY AGREEMENT Recorded Nov 8, 2022
From: IMMUNOCORE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061899/0866 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 030824 FRAME: 0150. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 10, 2020
From: IMMUNOCORE LIMITED
To: IMMUNOCORE LIMITED; ADAPTIMMUNE LIMITED
Reel/Frame 054373/0041 →
SECURITY INTEREST Recorded Nov 6, 2020
From: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
To: OXFORD FINANCE LUXEMBOURG S.À R.L., REGISTERED WITH THE LUXEMBOURG COMMERCIAL REGISTER UNDER NUMBER B243395, ACTING IN RESPECT OF ITS COMPARTMENT 1
Reel/Frame 054344/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: IMMUNOCORE LIMITED
To: ADAPTIMMUNE LIMITED; IMMUNOCORE LIMITED
Reel/Frame 030824/0150 →
CHANGE OF NAME Recorded Feb 20, 2012
From: AVIDEX LIMITED
To: MEDIGENE LIMITED
Reel/Frame 027731/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2012
From: JAKOBSEN, BENT KARSTEN; GLICK, MEIR
To: AVIDEX LIMITED
Reel/Frame 027731/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: MEDIGENE LIMITED
To: IMMUNOCORE LIMITED
Reel/Frame 022076/0044 →